左卡尼汀对儿童病毒性心肌炎白介素-18及诱导型一氧化氮合酶的影响  

Effects of Levocarnitine on Serum Levels of IL-18 and iNOS in Children with Viral Myocarditis

作　　者：顾坚[1] 鲍琼[1] 张仕超[1] 雷尚兵[1] 

机构地区：[1]湖北医药学院附属太和医院,湖北十堰442000

出　　处：《儿科药学杂志》2014年第2期5-7,共3页Journal of Pediatric Pharmacy

摘　　要：目的:探讨左卡尼汀对病毒性心肌炎(VMC)患儿白介素-18(IL-18)及诱导型一氧化氮合酶(iNOS)的影响。方法:将60例病毒性心肌炎患儿随机分为两组各30例,治疗组给予左卡尼汀100 mg/(kg·d)静脉滴注,对照组给予辅酶A 100 U/d和ATP 40 mg/d静脉滴注,疗程均为14 d。采用酶联免疫吸附法检测患儿治疗前后血清IL-18水平,比色法检测患儿治疗前后血清iNOS水平。结果:对照组治疗前后IL-18、iNOS水平比较差异无统计学意义(P>0.05);治疗组治疗后血清IL-18、iNOS水平显著下降,与治疗前比较差异有统计学意义[(133.66±44.82)vs(271.43±87.50),(8.31±2.19)vs(17.75±4.32),P<0.01],与对照组比较差异亦有统计学意义[(133.66±44.82)vs(243.29±80.93),(8.31±2.19)vs(14.18±3.94),P<0.01]。结论:左卡尼汀可降低VMC患儿血清IL-18及iNOS水平,对VMC有良好的治疗作用。Objective： To study the effects of Levocamitine on serum levels of IL-18 and iNOS in children with viral myocarditis. Methods： Sixty children with viral myocarditis were randomized into two groups. Levocarnitine injection 100 mg/（ kg d） was injected to the therapygroup （n=30） for fourteen days, while the control group （n=30） was injected with CoA 100 U/d＋ATP 40 mg/d for fourteen days. The serum levels of IL-18 were detected by ELISA, and iNOS were detected by calorimetry in all patients before and after fourteen days＇ treatment. Results： The serum levels of IL-18 and iNOS in the control group before and after the treatment were no significant difference （P〉0.05）. After the treatment, the serum levels of IL-18 and iNOS were significantly decreased in the therapy group; there was a significant difference compared with those before treatment [ （133. 66±. 82） vs （271.43±87.50）, （8.31＋2.19） vs （17.75＋4.32）, P〈0.01] ; compared with the control group, there was a significant difference [（133.66±44. 82） vs （243.29＋80. 93）, （8. 31±2. 19） vs （14. 18±3.94）, P〈0. 01. Conclusions： Levocamitine can reduce the serum levels of IL-18 and iNOS, and has a good therapeutic effect to viral myocarditis.

关 键 词：左卡尼汀 病毒 心肌炎 白介素-18 诱导型-氧化氮合酶 

分 类 号：R722.1[医药卫生—儿科]